Upgrades:
Kimco Realty (NYSE:KIM) was upgraded by equities researchers
at Evercore ISI to an "outperform" rating in a note issued to
investors on Monday, The Fly reports.
KIM has been the topic of several other research reports.
Capital One Financial raised Kimco Realty from an "equal weight"
rating to an "overweight" rating and set a $26.00 target price on the
stock in a research report on Monday, August 2nd. BTIG Research restated a "hold"
rating on shares of Kimco Realty in a research note on Sunday, September 26th.
Truist upped their price objective on Kimco Realty from $23.00 to $25.00 and
gave the stock a "buy" rating in a research note on Monday, August
30th. Truist Securities upped their target price on Kimco Realty from $23.00 to
$25.00 and gave the company a "buy" rating in a research report on
Monday, August 30th. Finally, Morgan Stanley upped their target price on Kimco
Realty from $25.00 to $26.00 and gave the company an "overweight"
rating in a research report on Thursday, August 19th. Three research analysts
have rated the stock with a hold rating and fourteen have assigned a buy rating
to the company's stock. According to MarketBeat, the stock has a consensus
rating of "Buy" and an average price target of $23.32.
KIM stock opened at $24.05 on Monday. Kimco Realty has a
twelve month low of $14.03 and a twelve month high of $24.95. The stock has a
market cap of $14.83 billion, a P/E ratio of 12.59, a PEG ratio of 2.11 and a beta
of 1.50. The business's 50-day moving average price is $22.55 and its 200-day
moving average price is $21.71. Read
more …
Royal Gold (NASDAQ:RGLD) (TSE:RGL) was upgraded by research
analysts at Bank of America from an "underperform" rating to a
"neutral" rating in a report issued on Monday, The Fly reports.
RGLD has been the topic of a number of other research
reports. TD Securities lowered their price objective on Royal Gold from $145.00
to $140.00 and set a "buy" rating on the stock in a report on Friday,
August 13th. Zacks Investment Research raised Royal Gold from a
"sell" rating to a "hold" rating and set a $106.00 price
objective on the stock in a report on Tuesday, October 26th. Raymond James set
a $136.00 price objective on Royal Gold and gave the company an
"outperform" rating in a report on Thursday, November 4th. BMO
Capital Markets lifted their price objective on Royal Gold from $138.00 to
$145.00 and gave the company a "market perform" rating in a report on
Friday, August 13th. Finally, National Bank Financial lowered their price
objective on Royal Gold from C$160.00 to C$155.00 and set a "sector
perform" rating on the stock in a report on Friday, September 10th. Six
research analysts have rated the stock with a hold rating and five have
assigned a buy rating to the company. According to data from MarketBeat, Royal
Gold has an average rating of "Hold" and an average price target of
$136.03.
NASDAQ RGLD opened at $105.43 on Monday. The company has a
quick ratio of 3.65, a current ratio of 3.85 and a debt-to-equity ratio of
0.04. Royal Gold has a 52-week low of $92.01 and a 52-week high of $129.69. The
business's 50-day moving average price is $101.26 and its 200 day moving
average price is $111.48. The firm has a market cap of $6.92 billion, a P/E
ratio of 26.10, a P/E/G ratio of 2.67 and a beta of 0.64. Read
more …
AbbVie (NYSE:ABBV) was upgraded by investment analysts at
Societe Generale from a "hold" rating to a "buy" rating in
a report issued on Tuesday, PriceTargets.com reports.
Several other analysts also recently weighed in on ABBV.
Mizuho lifted their price target on shares of AbbVie from $128.00 to $131.00
and gave the company a "buy" rating in a research note on Monday,
August 2nd. Argus increased their price target on AbbVie from $130.00 to
$140.00 and gave the stock a "buy" rating in a research report on
Thursday, August 5th. Truist Securities started coverage on AbbVie in a report
on Tuesday, July 27th. They issued a "buy" rating and a $117.00 price
objective for the company. Cowen upped their price objective on shares of AbbVie
from $120.00 to $130.00 and gave the stock an "outperform" rating in
a research note on Monday, August 23rd. Finally, Morgan Stanley raised their
target price on shares of AbbVie from $116.00 to $124.00 and gave the company
an "overweight" rating in a research report on Monday, November 1st.
One equities research analyst has rated the stock with a hold rating and
thirteen have given a buy rating to the company. According to MarketBeat.com,
the company currently has an average rating of "Buy" and an average
price target of $127.17.
ABBV stock traded up $3.23 during midday trading on Tuesday,
reaching $118.88. The company's stock had a trading volume of 8,594,465 shares,
compared to its average volume of 6,838,689. The company has a debt-to-equity
ratio of 5.45, a quick ratio of 0.91 and a current ratio of 1.01. The stock has
a fifty day simple moving average of $111.39 and a two-hundred day simple
moving average of $113.87. AbbVie has a 1 year low of $101.55 and a 1 year high
of $121.53. The firm has a market capitalization of $210.08 billion, a
price-to-earnings ratio of 28.30, a PEG ratio of 2.46 and a beta of 0.83. Read
more …
Best Buy (NYSE:BBY) was upgraded by research analysts at
Bank of America to a “buy” rating in a research report issued on Wednesday, The
Fly reports.
Several other equities research analysts also recently
weighed in on BBY. Wedbush raised Best Buy to a “buy” rating in a research
report on Wednesday, August 25th. DA Davidson raised Best Buy to a “buy” rating
in a research report on Wednesday, August 25th. Zacks Investment Research
reaffirmed a “buy” rating on shares of Best Buy in a research report on Friday,
September 10th. Jefferies Financial Group increased their price target on Best
Buy from $136.00 to $145.00 and gave the stock a “buy” rating in a research
report on Wednesday, August 25th. Finally, Citigroup restated a “buy” rating on
shares of Best Buy in a research report on Wednesday. One research analyst has
rated the stock with a sell rating, five have issued a hold rating and twelve
have issued a buy rating to the company’s stock. According to data from
MarketBeat, the stock presently has an average rating of “Buy” and an average
target price of $128.31. Read
more …
Bank of Nova Scotia (NYSE:BNS) (TSE:BNS) was upgraded by
equities researchers at Canaccord Genuity from a “hold” rating to a “buy”
rating in a research note issued on Wednesday, The Fly reports.
Other equities analysts have also issued research reports
about the stock. National Bank Financial increased their target price on shares
of Bank of Nova Scotia from $84.00 to $86.00 and gave the company a “sector
perform” rating in a report on Wednesday, August 25th. TD Securities reduced
their target price on shares of Bank of Nova Scotia from C$90.00 to C$87.00 and
set a “buy” rating on the stock in a report on Wednesday, August 25th. Veritas
Investment Research reaffirmed a “buy” rating on shares of Bank of Nova Scotia
in a report on Friday, November 12th. Royal Bank of Canada increased their
target price on shares of Bank of Nova Scotia from C$86.00 to C$89.00 and gave
the company an “outperform” rating in a report on Wednesday, August 25th.
Finally, Zacks Investment Research cut shares of Bank of Nova Scotia from a
“buy” rating to a “hold” rating in a research report on Tuesday. Four research
analysts have rated the stock with a hold rating and eight have given a buy
rating to the company’s stock. According to MarketBeat.com, Bank of Nova Scotia
presently has an average rating of “Buy” and an average target price of $86.43.
Read
more …
Chevron (NYSE:CVX) was upgraded by stock analysts at Royal
Bank of Canada from a "sector perform" rating to an
"outperform" rating in a research note issued on Wednesday, The Fly
reports.
A number of other research firms also recently issued
reports on CVX. TheStreet upgraded shares of Chevron from a "c"
rating to a "b-" rating in a research report on Friday, July 30th.
Zacks Investment Research downgraded shares of Chevron from a "buy"
rating to a "hold" rating and set a $100.00 target price for the
company. in a research report on Tuesday, September 21st. Wells Fargo &
Company increased their target price on shares of Chevron from $109.00 to
$115.00 and gave the stock an "equal weight" rating in a research
report on Monday, November 1st. DZ Bank downgraded shares of Chevron from a
"buy" rating to a "hold" rating and set a $110.00 target
price for the company. in a research report on Wednesday, August 4th. Finally,
Morgan Stanley raised their price target on shares of Chevron from $149.00 to
$155.00 and gave the company an "overweight" rating in a report on
Friday, November 19th. Ten research analysts have rated the stock with a hold
rating and sixteen have given a buy rating to the company. Based on data from
MarketBeat.com, the stock currently has an average rating of "Buy"
and an average target price of $120.65.
Chevron stock opened at $116.30 on Wednesday. The company
has a 50 day moving average price of $108.83 and a 200 day moving average price
of $104.82. Chevron has a 52 week low of $83.53 and a 52 week high of $118.08.
The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a
current ratio of 1.28. The firm has a market capitalization of $224.19 billion,
a price-to-earnings ratio of 22.45, a P/E/G ratio of 2.42 and a beta of 1.30. Read
more …
Downgrades:
AstraZeneca (NASDAQ:AZN) was downgraded by stock analysts at
Bryan, Garnier & Co to a “buy” rating in a research note issued to
investors on Monday, The Fly reports.
Several other brokerages have also issued reports on AZN.
SVB Leerink lifted their price target on AstraZeneca from $71.00 to $73.00 and
gave the company an “outperform” rating in a research note on Monday, September
27th. JPMorgan Chase & Co. assumed coverage on AstraZeneca in a research
note on Thursday, August 12th. They issued an “overweight” rating on the stock.
Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of
AstraZeneca in a research note on Monday, October 11th. UBS Group restated a
“buy” rating on shares of AstraZeneca in a research report on Tuesday, October
19th. Finally, Morgan Stanley restated an “overweight” rating on shares of
AstraZeneca in a research report on Friday, September 17th. One analyst has
rated the stock with a sell rating, one has assigned a hold rating and twelve
have assigned a buy rating to the stock. According to MarketBeat, the stock has
a consensus rating of “Buy” and an average price target of $124.00. Read
more …
Pembina Pipeline (NYSE:PBA) (TSE:PPL) was downgraded by
equities researchers at CIBC from an "outperform" rating to a
"neutral" rating in a note issued to investors on Monday, The Fly
reports.
A number of other analysts also recently commented on the company.
TD Securities upped their price objective on Pembina Pipeline from C$43.00 to
C$45.00 and gave the stock a "buy" rating in a report on Monday,
November 8th. Royal Bank of Canada upped their price objective on Pembina
Pipeline from C$42.00 to C$48.00 and gave the stock an "outperform"
rating in a report on Monday, August 9th. Scotiabank upped their price
objective on Pembina Pipeline from C$42.00 to C$43.00 and gave the stock a
"sector perform" rating in a report on Friday, November 5th. Credit
Suisse Group initiated coverage on Pembina Pipeline in a report on Wednesday,
August 18th. They set a "neutral" rating for the company. Finally,
BMO Capital Markets initiated coverage on shares of Pembina Pipeline in a
research report on Wednesday, July 28th. They set a "market perform"
rating for the company. One analyst has rated the stock with a sell rating, ten
have given a hold rating and four have given a buy rating to the stock.
According to data from MarketBeat, the company has an average rating of
"Hold" and a consensus target price of $40.40.
Shares of NYSE:PBA traded down $1.03 during trading on
Monday, hitting $31.87. 81,796 shares of the stock were exchanged, compared to
its average volume of 1,108,605. The company has a fifty day moving average
price of $32.77 and a two-hundred day moving average price of $32.19. The
company has a market cap of $17.54 billion, a PE ratio of -132.79, a P/E/G
ratio of 5.35 and a beta of 1.43. The company has a current ratio of 0.54, a
quick ratio of 0.52 and a debt-to-equity ratio of 0.84. Pembina Pipeline has a
12-month low of $23.48 and a 12-month high of $34.73. Read
more …
Royal Bank of Canada (NYSE:RY) (TSE:RY) was downgraded by
investment analysts at Bank of America from a “neutral” rating to an
“underperform” rating in a research note issued to investors on Monday, The Fly
reports.
Several other analysts have also recently weighed in on RY.
Desjardins lifted their price objective on shares of Royal Bank of Canada from
C$138.00 to C$141.00 and gave the stock a “buy” rating in a research note on
Friday, August 27th. Zacks Investment Research cut shares of Royal Bank of
Canada from a “buy” rating to a “hold” rating in a research note on Saturday,
November 13th. Scotiabank lifted their price objective on shares of Royal Bank
of Canada from C$144.00 to C$148.00 in a research note on Tuesday, August 17th.
Fundamental Research lifted their price objective on shares of Royal Bank of
Canada from $127.27 to $143.76 and gave the stock a “buy” rating in a research
note on Wednesday, September 1st. Finally, Credit Suisse Group boosted their
target price on shares of Royal Bank of Canada from C$135.00 to C$140.00 and
gave the company an “outperform” rating in a research report on Thursday,
August 26th. One research analyst has rated the stock with a sell rating, three
have given a hold rating and eight have assigned a buy rating to the company’s
stock. According to data from MarketBeat, the stock has an average rating of
“Buy” and a consensus price target of $134.48. Read
more …
Ventas (NYSE:VTR) was downgraded by equities researchers at
Sumitomo Mitsui Financial Group from an "outperform" rating to a
"neutral" rating in a report issued on Monday, Price Targets.com
reports. They currently have a $55.00 price objective on the real estate
investment trust's stock. Sumitomo Mitsui Financial Group's price target
indicates a potential upside of 7.11% from the stock's current price.
Other equities analysts also recently issued reports about
the company. Capital One Financial restated an "equal weight" rating
on shares of Ventas in a report on Friday, November 5th. Raymond James upgraded
Ventas from an "outperform" rating to a "strong-buy" rating
and increased their target price for the company from $65.00 to $67.00 in a
research note on Thursday, September 23rd. BMO Capital Markets upgraded Ventas
from an "underperform" rating to a "market perform" rating
and set a $60.00 target price for the company in a research note on Thursday,
August 26th. Deutsche Bank Aktiengesellschaft upgraded Ventas from a
"hold" rating to a "buy" rating and increased their target
price for the company from $61.00 to $66.00 in a research note on Tuesday,
September 7th. Finally, Morgan Stanley started coverage on Ventas in a research
note on Monday, October 4th. They issued an "equal weight" rating and
a $60.00 target price for the company. Eight analysts have rated the stock with
a hold rating, six have issued a buy rating and one has issued a strong buy
rating to the company. Based on data from MarketBeat.com, the company has an average
rating of "Buy" and a consensus target price of $59.24.
Ventas stock opened at $51.35 on Monday. The stock's 50-day
moving average is $55.15 and its 200-day moving average is $56.34. The company
has a market cap of $20.50 billion, a price-to-earnings ratio of 96.89, a
price-to-earnings-growth ratio of 4.94 and a beta of 1.17. The company has a
debt-to-equity ratio of 1.08, a current ratio of 0.59 and a quick ratio of
0.71. Ventas has a 12 month low of $45.40 and a 12 month high of $61.09. Read
more …
National Bank of Canada (TSE:NA) was downgraded by research
analysts at Scotiabank to a “hold” rating in a report issued on Tuesday,
TipRanks reports. They presently have a C$113.00 target price on the financial
services provider’s stock. Scotiabank’s price target points to a potential
upside of 7.38% from the company’s previous close.
NA has been the topic of several other reports. Canaccord Genuity
boosted their target price on National Bank of Canada from C$101.00 to C$103.50
and gave the stock a “hold” rating in a report on Thursday, August 26th.
Barclays cut National Bank of Canada to a “sell” rating and set a C$100.00
target price on the stock. in a report on Monday, November 15th. BMO Capital
Markets boosted their target price on National Bank of Canada from C$101.00 to
C$104.00 and gave the stock an “outperform” rating in a report on Thursday,
August 26th. Credit Suisse Group restated a “neutral” rating on shares of
National Bank of Canada in a report on Thursday, September 2nd. Finally,
Cormark lifted their price target on shares of National Bank of Canada from
C$109.00 to C$112.00 and gave the company a “buy” rating in a research report
on Thursday, August 26th. One analyst has rated the stock with a sell rating,
six have issued a hold rating and four have given a buy rating to the stock.
According to MarketBeat, the company currently has a consensus rating of “Hold”
and a consensus target price of C$100.23. Read
more …
